| T regulatory cells support plasma cell populations in the bone marrow AG Zaretsky, C Konradt, F Dépis, JB Wing, R Goenka, DG Atria, JS Silver, ... Cell reports 18 (8), 1906-1916, 2017 | 114 | 2017 |
| Pivotal involvement of Fcγ receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1 I Dunn-Siegrist, O Leger, B Daubeuf, Y Poitevin, F Dépis, S Herren, ... Journal of biological chemistry 282 (48), 34817-34827, 2007 | 58 | 2007 |
| Selective antibody intervention of Toll-like receptor 4 activation through Fc γ receptor tethering L Shang, B Daubeuf, M Triantafilou, R Olden, F Dépis, AC Raby, S Herren, ... Journal of Biological Chemistry 289 (22), 15309-15318, 2014 | 43 | 2014 |
| Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity EM Tam, RB Fulton, JF Sampson, M Muda, A Camblin, J Richards, ... Science translational medicine 11 (512), eaax0720, 2019 | 42 | 2019 |
| Unstable FoxP3+ T regulatory cells in NZW mice F Dépis, HK Kwon, D Mathis, C Benoist Proceedings of the National Academy of Sciences U S A, 2016 | 30 | 2016 |
| Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases Y Dean, F Dépis, M Kosco-Vilbois Swiss medical weekly 142 (4748), w13711-w13711, 2012 | 25 | 2012 |
| Long‐term amelioration of established collagen‐induced arthritis achieved with short‐term therapy combining anti‐CD3 and anti–tumor necrosis factor treatments F Dépis, E Hatterer, C Lamacchia, JM Waldburger, C Gabay, W Reith, ... Arthritis & Rheumatism 64 (10), 3189-3198, 2012 | 17 | 2012 |
| Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists Y Dean, F Depis US Patent App. 13/354,813, 2012 | 16 | 2012 |
| Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 … JD Weaver, EC Stack, JA Buggé, C Hu, L McGrath, A Mueller, M Wong, ... Oncoimmunology 11 (1), 2141007, 2022 | 15 | 2022 |
| Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells F Dépis, C Hu, J Weaver, L McGrath, B Klebanov, J Buggé, B Umiker, ... Cancer Research 80 (16_Supplement), 4532-4532, 2020 | 9 | 2020 |
| Characterization of a surrogate murine antibody to model anti-human CD3 therapies F Depis, E Hatterer, R Ballet, B Daubeuf, L Cons, S Glatt, W Reith, ... MAbs 5 (4), 555-564, 2013 | 8 | 2013 |
| Antibodies that bind chemokine (CC motif) receptor 8 (CCR8) LL Mcgrath, F Dépis, HU Changyun, LG Presta, JA Buggé US Patent 11,692,038, 2023 | 4* | 2023 |
| Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists Y Dean, F Depis US Patent App. 16/683,584, 2020 | 1 | 2020 |
| Stable Expression of FOXP3 and Core Tolerogenic Genes by Engineered Human Tregs P Zarin, M Sassone-Corsi, A Doherty, A Chicoine, V DeVault, X Li, J Yam, ... The Journal of Immunology 210 (1_Supplement), 85.09-85.09, 2023 | | 2023 |
| Adoptive Transfer of Murine Engineered T Regulatory Cells Ameliorates Disease in a Model of Lipopolysaccharide Induced Acute Lung Injury M Hoover, P Zarin, M Milaszewski, CE Frias, A Doherty, NR Reed, ... A21. INFECTION, LUNG INJURY, AND SEPSIS FROM MODELS TO TRANSLATION, A1089-A1089, 2023 | | 2023 |
| Anti-tnfr2 antibodies and uses thereof EM Tam, M Muda, KA Raue, VB Kurella, DC Drummond, RB Fulton, ... US Patent App. 17/276,686, 2021 | | 2021 |
| Targeting TNFR2-A key regulator of the tumor immunosuppressive microenvironment A Raue, R Fulton, J Sampson, A Camblin, J Richards, Y Jiao, L Xu, ... EUROPEAN JOURNAL OF CANCER 103, E81-E81, 2018 | | 2018 |
| Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists Y Dean, F Depis US Patent App. 14/220,863, 2014 | | 2014 |
| Factors and Mechanisms Controlling the Generation of Tregs in the Thymus F Depis, D Mathis, C Benoist DIABETES 62, A718-A718, 2013 | | 2013 |
| Short Combination Therapy with Anti-CD3 and Anti-TNF Is Associated with Long Term Inhibition of Established Collagen-Induced Arthritis F Depis, E Hatterer, C Lamacchia, C Gabay, JM Waldburger, W Reith, ... ARTHRITIS AND RHEUMATISM 63 (10), S912-S912, 2011 | | 2011 |
